Terry S Kang1, Ken Lord, Nancy Kunjukunju. 1. *Department of Ophthalmology, University of Missouri-Kansas City, Kansas City, Missouri; and †Retina Associates of Southern Utah, St. George, Utah.
Abstract
PURPOSE: To report the first known case of spontaneous choroidals in association with a patient on dabigatran etexilate. METHODS: Observational case report. RESULTS: An 82-year-old man on 150 mg dabigatran etexilate by mouth twice a day for atrial fibrillation developed spontaneous choroidal hemorrhage in his left eye. No other causes were found after careful history and examination. CONCLUSION: Dabigatran is a popular new alternative to warfarin that has no blood monitoring or reversal agent. Physicians should be aware of this new medication and its possible hemorrhagic complications.
PURPOSE: To report the first known case of spontaneous choroidals in association with a patient on dabigatran etexilate. METHODS: Observational case report. RESULTS: An 82-year-old man on 150 mg dabigatran etexilate by mouth twice a day for atrial fibrillation developed spontaneous choroidal hemorrhage in his left eye. No other causes were found after careful history and examination. CONCLUSION:Dabigatran is a popular new alternative to warfarin that has no blood monitoring or reversal agent. Physicians should be aware of this new medication and its possible hemorrhagic complications.